How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer

摘要: Background. Gastriccancer(GC)isthesecondleadingcauseof cancer death worldwide. GC is a heterogeneous disease in terms of histology, anatomy, and epidemiology. There also widevariabilityinhowGCistreatedinboththeresectableand unresectable settings. Identification prognostic predictivebiomarkersiscriticaltohelpdirectandtailortherapyfor this deadly disease. Methods. A literature search was done using Medline MeSH for predictive biomarkers biomarkers.The limited to human subjects the English language.There no limit on dates. Published data andunpublishedabstractswithclinicalrelevancewereincluded. Results. Manypotentialprognosticandpredictivebiomarkers have been assessed GC, some which are becoming practice changing.This review focused clinically relevant biomarkers, including EGFR, HER2, various markers angiogenesis, proto-oncogene MET, mammalian target rapamycin. Conclusion. beginning change our understanding prognosis management. The recognition such as HER2 vascular endothelial growth factor, has an exciting development management validating use targeted drugs trastuzumab ramucirumab.METisanotherpotentialpredictivemarkerthat may be with rilotumumab, foretinib, crizotinib. Further identification validation potential transformhowthisdeadlydiseaseismanaged.TheOncologist 2014;19:1046–1055